{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T04:14:25Z","timestamp":1728965665012},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,5,30]],"date-time":"2014-05-30T00:00:00Z","timestamp":1401408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,5,30]],"date-time":"2014-05-30T00:00:00Z","timestamp":1401408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pegloticase is a powerful but underutilized weapon in the rheumatologist\u2019s armamentarium. The drug\u2019s immunogenicity leads to neutralizing antibody formation and rapid loss of efficacy in roughly one-half of all patients, which remains an impediment to broader use. New data, however, suggest that drug survival might improve with concomitant immunosuppressive agent (s), which merits further study. Efficacy appears to be unchanged when pegloticase is infused at 3-week (rather than 2-week) intervals. Stretching the time between infusions may also improve patient adherence and allow for earlier identification of transient responders.<\/jats:p>","DOI":"10.1186\/ar4572","type":"journal-article","created":{"date-parts":[[2014,5,30]],"date-time":"2014-05-30T09:08:39Z","timestamp":1401440919000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PEG-ing down (and preventing?) the cause of pegloticase failure"],"prefix":"10.1186","volume":"16","author":[{"given":"Aryeh M","family":"Abeles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,30]]},"reference":[{"key":"4191_CR1","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar4500","volume":"16","author":"MS Hershfield","year":"2014","unstructured":"Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS: Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther. 2014, 16: R63-10.1186\/ar4500.","journal-title":"Arthritis Res Ther"},{"key":"4191_CR2","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s11095-013-1067-7","volume":"30","author":"H Schellekens","year":"2013","unstructured":"Schellekens H, Hennink WE, Brinks V: The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res. 2013, 30: 1729-1734. 10.1007\/s11095-013-1067-7.","journal-title":"Pharm Res"},{"key":"4191_CR3","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/ar4497","volume":"16","author":"PE Lipsky","year":"2014","unstructured":"Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, Becker MA: Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014, 16: R60-10.1186\/ar4497.","journal-title":"Arthritis Res Ther"},{"key":"4191_CR4","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998, 41: 1552-1563. 10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W.","journal-title":"Arthritis Rheum"},{"key":"4191_CR5","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","volume":"71","author":"CL Krieckaert","year":"2012","unstructured":"Krieckaert CL, Nurmohamed MT, Wolbink GJ: Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012, 71: 1914-1915. 10.1136\/annrheumdis-2012-201544.","journal-title":"Ann Rheum Dis"},{"key":"4191_CR6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","volume":"45","author":"MC Kapetanovic","year":"2006","unstructured":"Kapetanovic MC, Saxne T, Sj\u00f6holm A, Truedsson L, J\u00f6nsson G, Geborek P: Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006, 45: 106-111. 10.1093\/rheumatology\/kei193.","journal-title":"Rheumatology (Oxford)"},{"key":"4191_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","volume":"124","author":"RT Keenan","year":"2011","unstructured":"Keenan RT, O\u2019Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, Krasnokutsky S, Oh C, Pillinger MH: Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011, 124: 155-163. 10.1016\/j.amjmed.2010.09.012.","journal-title":"Am J Med"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4572.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4572\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4572.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:16:28Z","timestamp":1728922588000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,30]]},"references-count":7,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,6]]}},"alternative-id":["4191"],"URL":"https:\/\/doi.org\/10.1186\/ar4572","relation":{},"ISSN":["1478-6354"],"issn-type":[{"type":"electronic","value":"1478-6354"}],"subject":[],"published":{"date-parts":[[2014,5,30]]},"assertion":[{"value":"30 May 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"112"}}